Overview US Zamto-cel Autoimmune Diseases Status: NOT_YET_RECRUITING Trial end date: 2026-12-01 Target enrollment: Participant gender: Summary AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.Phase: PHASE1 Details Lead Sponsor: Miltenyi Biomedicine GmbHTreatments: Cyclophosphamidefludarabine